499 related articles for article (PubMed ID: 29407368)
21. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
[TBL] [Abstract][Full Text] [Related]
22. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
Zargari O; Azimi SZ; Geranmayeh S
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
[TBL] [Abstract][Full Text] [Related]
23. A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.
Dessinioti C; Plaka M; Soura E; Mortaki D; Papaxoinis G; Gogas H; Stratigos AJ
Oncologist; 2019 Aug; 24(8):e755-e764. PubMed ID: 31073024
[TBL] [Abstract][Full Text] [Related]
24. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
25. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Ali FR; Lear JT
Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
[TBL] [Abstract][Full Text] [Related]
27. Treatments on the horizon for locally advanced basal cell carcinoma.
Idriss MH; Stull CM; Migden MR
Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
[TBL] [Abstract][Full Text] [Related]
28. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
Lyons TG; O'Kane GM; Kelly CM
Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
[TBL] [Abstract][Full Text] [Related]
30. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
31. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic treatment options for advanced epithelial skin cancer.
Soura E; Chasapi V; Stratigos AJ
Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
[TBL] [Abstract][Full Text] [Related]
33. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma.
Sanmartín O; Llombart B; Carretero Hernández G; Flórez Menéndez Á; Botella-Estrada R; Herrera Ceballos E; Puig S
Actas Dermosifiliogr (Engl Ed); 2021 Apr; 112(4):295-301. PubMed ID: 33197438
[TBL] [Abstract][Full Text] [Related]
34. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
35. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
Peris K; Fargnoli MC; Garbe C; Kaufmann R; Bastholt L; Seguin NB; Bataille V; Marmol VD; Dummer R; Harwood CA; Hauschild A; Höller C; Haedersdal M; Malvehy J; Middleton MR; Morton CA; Nagore E; Stratigos AJ; Szeimies RM; Tagliaferri L; Trakatelli M; Zalaudek I; Eggermont A; Grob JJ;
Eur J Cancer; 2019 Sep; 118():10-34. PubMed ID: 31288208
[TBL] [Abstract][Full Text] [Related]
37. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
[TBL] [Abstract][Full Text] [Related]
38. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
39. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
[TBL] [Abstract][Full Text] [Related]
40. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]